【摘要】 目的探讨布地奈德联合伏立康唑在慢性阻塞性肺疾病(COPD)合并肺部真菌感染治疗中的安全性、有效性。方法选择COPD合并肺部真菌感染患者110例,根据随机数字表法分为观察组和对照组,各55例。对照组予以布地奈德治疗,观察组予以布地奈德+伏立康唑治疗,治疗2周。比较两组患者治疗前后的血清炎症因子变化,以及临床疗效和不良反应。结果观察组临床总有效率明显高于对照组,差异有统计学意义(χ~2=10.53,P<0.05)。两组患者治疗后肿瘤坏死因子-α(TNF-α)、血清白介素-6(IL-6)、白介素-10(IL-10)水平均明显低于治疗前,差异均有统计学意义(t分别=21.51、60.81、51.22、9.55、28.80、29.02,P均<0.05),且观察组患者治疗后TNF-α、IL-6、IL-10水平均低于对照组治疗后,差异均有统计学意义(t分别=14.26、27.82、38.32,P均<0.05)。两组不良反应发生率比较,差异无统计学意义(χ~2=0.21,P>0.05)。结论布地奈德联合伏立康唑可有效减轻COPD合并肺部真菌感染患者临床症状及炎症反应,且不良反应较少。更多还原

【Abstract】 Objective To explore the safety and effectiveness of budesonide combined with voriconazole in the treatment of chronic obstructive pulmonary disease(COPD)with pulmonary fungal infection. Methods Totally 110 patients with COPD and pulmonary fungal infection were selected and divided into observation group and control group according to the random number table method,with 55 cases in each group.The control group was given nalbudesonide treatment,and the observation group was given nalbudesonide combined with voriconazole treatment for 2 weeks.The changes of serum inflammatory factors before and after treatment of the two groups were compared as well as the clinical efficacy and adverse reactions. Results The total clinical effective rate of the observation group was significantly higher than that of the control group（χ~2=10.53,P<0.05）.Tumor necrosis factor-α（TNF-α）,interleukin-6(IL-6),interleukin-10(IL-10)after treatment in the two groups were significantly lower than before treatment(t=21.51,60.81,51.22,9.55,28.80,29.02,P<0.05),and the TNF-α,IL-6,IL-10 in the observation group after treatment were lower than those in the control group(t=14.26,27.82,38.32,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups（χ~2=0.21,P>0.05）. Conclusion Budesonide combined with voriconazole can effectively alleviate the clinical symptoms and inflammatory response in patients with COPD complicated with pulmonary fungal infection,with fewer adverse reactions.更多还原